FindTrial
Sign In

To compare intravenous treosulphan with intravenous treosulphan plus cisplatin in advanced ovarian cancer

To compare intravenous treosulphan with intravenous treosulphan plus cisplatin in advanced ovarian cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN59482963
Enrollment
Unknown
Registered
2002-08-19
Start date
1993-01-01
Completion date
Unknown
Last updated
2019-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian cancer Cancer Ovarian

Interventions

Patients are randomised to one of two treatment arms: 1. Arm A: Treosulphan given every 3 weeks 2. Arm B: Treosulphan plus cisplatin repeated every 3 weeks

Sponsors

Leo Pharmaceuticals
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. International Federation of Gynecology and Obstetrics (FIGO) stage Ic or II (except well differentiated), III or IV ovarian cancer 2. Histological confirmation of carcinoma of epithelial origin 3. Aged 75 or under 4. Life expectancy >2 months 5. No extensive prior chemotherapy (no prior treosulfan or cisplatin at all, and not more than one course of other cytotoxic treatment) 6. No radical prior radiotherapy to pelvis and/or abdomen within preceding 3 months 7. No depressed marrow function or gastro-intestinal bleeding 8. Good renal function

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

MeasureTime frame
Not provided at time of registration—

Secondary

MeasureTime frame
Not provided at time of registration—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026